LIMKi 3

Key Product Details

Product Description

LIMKi 3 is a potent LIM kinase inhibitor (IC₅₀ values are 7 and 8 nM for LIMK1 and LIMK2 respectively). Inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. Reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.

Product Specifications for LIMKi 3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for LIMKi 3

The following data is based on the product molecular weight 431.29.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.32 mL	11.59 mL	23.19 mL
5 mM	0.46 mL	2.32 mL	4.64 mL
10 mM	0.23 mL	1.16 mL	2.32 mL
50 mM	0.05 mL	0.23 mL	0.46 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 27 publications citing the usage of this product.

• Scott LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J.Cell Biol. 2010 PMID: 20876278
• Sparrow The actin-severing protein cofilin is downstream of neuregulin signaling and is essential for Schwann cell myelination. J.Neurosci. 2012 PMID: 22496574
• Ross-Macdonald Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol.Cancer Ther. 2008 PMID: 19001433

Product Documents for LIMKi 3